The identification/selection of appropriate patient subgroups with asymptomatic carotid artery stenosis and the performance of prophylactic carotid endarterectomy (CEA)/carotid artery stenting (CAS) exclusively on these asymptomatic patient subgroups is currently one of the "hottest" topics in vascular surgery. It is now clear that offering CEA/CAS to asymptomatic carotid patients based only on the degree of carotid stenosis is unjustified and scientifically flawed. On the other hand, offering only best medical therapy to every asymptomatic patient, irrespective of certain high-risk criteria (such as the detection of microemboli by transcranial Doppler, intraplaque hemorrhage, silent embolic infarcts on brain computed tomography/magnetic resonance imaging, elevated biomarkers, family history), is equally wrong. The validation of specific measures to identify those asymptomatic patients at high risk for developing symptoms is crucial to achieve optimal use of carotid interventions and avoid wasting stroke prevention resources.
Introduction
The management of asymptomatic carotid stenosis is currently one of the most controversial and debated topics. Until not long ago, offering prophylactic carotid endarterectomy (CEA) to patients with asymptomatic carotid stenosis was justified based on the results of 3 landmark randomized controlled trials (RCTs). [1] [2] [3] All these RCTs showed an almost 6% 5-year relative risk reduction in stroke with CEA compared with best medical therapy (BMT). More recently, however, improvements in what constitutes "current BMT" have led to questioning the applicability of the results of these landmark RCTs 1-3 at present. [4] [5] [6] [7] [8] There have been calls for new RCTs, the need to revise carotid guidelines, and even stop operating on asymptomatic patients. 9, 10 Unfortunately, the Stent Protected Angioplasty versus Carotid Endarterectomy (SPACE)-2 trial has been stopped 11 and the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)-2 has only recently started recruiting patients. 12 The present narrative review will attempt to reconcile the conflicting views and show why appropriate asymptomatic patient selection for carotid revascularization procedures is urgently needed.
Are All Asymptomatic Patients Equal?
It is now clear that a "one-size-fits-all" approach for every patient with asymptomatic carotid stenosis is wrong. Offering prophylactic CEA/carotid artery stenting (CAS) to every asymptomatic patient is equally wrong as is offering only BMT and refusing to operate on some of these patients. All patients who develop an ischemic stroke were asymptomatic the day before their event. Some of these patients may not have been aware that they had asymptomatic carotid artery stenosis; others, however, did know of their disease and even implemented the appropriate preventive measures (ie, smoking cessation, maintenance of a healthy body weight, moderate exercise, blood pressure and diabetes control, an antiplatelet agent, and a statin). 13 In registry databases, 14,15 the main factor affecting outcomes was the symptomatic status of the patients underlying the importance of proper and timing patient selection.
The fact that not all asymptomatic patients carry the same stroke risk was demonstrated in the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study. [16] [17] [18] In ACSRS, 1121 patients with 50% to 99% asymptomatic carotid stenosis received BMT and were followed up for 6 to 96 months (mean 48 months). A combination of several criteria (eg, severity of stenosis, a history of contralateral transient ischemic attack [TIA] episodes, and a number of plaque texture features at baseline) could stratify patients into groups of varying annual stroke rate from <1% to >10%. 16 Furthermore, the presence of a juxtaluminal black area of >8 mm 2 in a plaque (indicating a thrombus or a very thin or absent fibrous cap) led to the identification of a group of 245 patients who had an average annual stroke rate of 4.1% and contained 86% of the strokes that occurred during follow-up. 18 The presence of microemboli on transcranial Doppler is another feature that can categorize patients as high or low risk for stroke. The predictive value of microemboli detection on transcranial Doppler for the identification of asymptomatic patients at high risk for stroke has been validated by 2 independent studies and is further supported by a metaanalysis. 8, 19, 20 The detection of 2 embolic signals in a single 1-hour recording suggests a high-risk, unstable asymptomatic plaque or a plaque with a thrombus on its surface. 21 Several other prognostic signs/methods have been suggested to identify asymptomatic patients at high risk of becoming symptomatic. These include silent embolic infarcts on brain computed tomography or magnetic resonance imaging scans, the presence of intraplaque hemorrhage, reduced cerebral blood flow reserve, and so on. 13 For some of these methods, there is still insufficient evidence, while for others the data are more robust. 13 Irrespective of the verification of the validity of some of these methods, the suggestion that some (or all) of these methods can positively identify patients with asymptomatic carotid who could benefit from intervention already implies that not all asymptomatic patients are the same. Then why should all asymptomatic patients be offered the same treatment? Meanwhile the neurological community is adopting new definitions for asymptomatic patients, recognizing that patients with silent infarcts represent a specific group requiring particular attention and therapeutic strategies. 22 
Individualization of Treatment
Besides identifying asymptomatic patients who are at high risk for stroke and warrant a prophylactic carotid revascularization procedure, another important question is "will these patients undergo CAS or CEA"? Not all patients are candidates for both procedures. Some patients may have a contraindication for CEA, while others may have a contraindication for CAS.
A recent article discussed CAS risk assessment and identified a number of factors that increase stroke risk associated with CAS. 23 For example, increasing age is a predictor of clinical events following CAS. The CREST subanalysis by age showed that "age acted as a treatment effect modifier for the primary end point (P ¼ .02)." 24 Carotid artery stenting was associated with similar periprocedural stroke rates with CEA only in patients <65 years of age. 24 For patients aged 65 to 74 years, CAS was associated with almost double the periprocedural stroke rates compared with CEA, but due to the wide confidence interval (CI), this difference did not reach statistical significance (3.8% vs 2.0%, respectively; hazard ratio [HR] for CAS: 1.98; 95% CI: 0.93-4.23; P ¼ .08). 24 However, for patients 75 years, CAS was associated with a significant >2-fold higher periprocedural stroke rate compared with CEA (6.9% vs 3.1%, respectively; HR: 2.17; 95% CI: 1.06-4.45; P ¼ .035). 24 It has recently been suggested that revascularization of asymptomatic carotid stenosis is not appropriate in patients on dialysis. 25 The outcomes of a total of 2131 dialysis patients with asymptomatic carotid stenosis were reviewed (1805 CEA, 326 CAS). 25 The 30-day mortality rate was 4.7% (4.6% for CEA; 4.9% for CAS; P ¼ .807), while the 30-day stroke rates were 6.5% (6.4% for CEA; 6.9% CAS; P ¼ .774) and 1-year stroke rates were 13.6% (13.3% for CEA; 15.0% for CAS; P ¼ .490). Cardiac complications occurred in 22.0% of patients at 30 days (22.2% for CEA; 20.6% for CAS; P ¼ .525). The combined 30-day stroke/death rate was 10.2% (10.1% for CEA; 10.9% for CAS; P ¼ .490), while the 1-year stroke/death rate was 33.5% (32.2% for CEA; 39.6% for CAS; P ¼ .025). 25 There is little doubt that these outcomes are unacceptable for patients who are completely asymptomatic.
Another factor that should be taken under consideration when offering a carotid revascularization procedure is whether the patient will live long enough to benefit from this procedure. A well-designed study assessed prospectively collected data from 4114 isolated CEAs performed for asymptomatic stenosis across 24 centers in the Vascular Study Group of New England between 2003 and 2011. 26 Increasing age, diabetes, smoking history, congestive heart failure, chronic obstructive pulmonary disease, poor renal function (estimated glomerular filtration rate <60 mL/min or dialysis dependence), absence of statin use, and worse contralateral internal carotid artery stenosis were all associated with worse survival. The conclusion reached was that high-risk patients (such as those with multiple major risk factors including age 80 years, insulin-dependent diabetes, dialysis dependence, and severe contralateral internal carotid artery stenosis) are unlikely to survive long enough to realize a benefit of prophylactic CEA for asymptomatic stenosis. 26 The same group evaluated information from an administrative data set, the American College of Surgeons National Quality Improvement Project, and identified 8 conditions from the literature that are likely to reduce long-term survival. 27 Such conditions included disseminated cancer, advanced liver disease, symptomatic congestive heart failure, dialysis dependence, chronic obstructive pulmonary disease, cancer, and high American Society of Anesthesia risk scores. Of 12 631 CEAs performed in asymptomatic patients, 20% were performed in patients who had at least one of the conditions associated with reduced life expectancy. 27 It was shown that in patients with comorbidities associated with decreased survival there was an almost 3-fold increased risk of perioperative stroke or death compared with those patients without these conditions (odds ratio: 2.8; 95% CI: 2.1-3.8; P < .001). 27 The accompanying editorial 28 criticized the conclusions reached by the authors (ie, that the net benefit of CEA in this population remains uncertain) 27 and supported that these results call for increased awareness regarding who is really a candidate for carotid interventions. These outcomes clearly demonstrate that clinical governance is of key importance in determining which patients will actually benefit from a procedure that is intended to prevent stroke rather than causing it.
Certain anatomic/physiological characteristics may also comprise a relative contraindication to one technique or the other. Carotid plaque calcification, tortuous carotid arteries, or a bovine aortic arch are examples of when CAS should better be avoided. 23 On the other hand, a tracheostomy or a scarred neck due to irradiation may increase the difficulty of CEA and be relative contraindications for this procedure. Diabetes may also pose a higher risk with CEA (but not with CAS). 29 Finally, a frail elderly (eg, >95 years) patient with asymptomatic carotid stenosis may be better off managed by BMT alone despite the presence of anatomic/physiologic factors rendering him or her at high risk for stroke. Individualization of treatment is essential to achieve the best outcome for each individual patient.
Although ideally several RCTs would be necessary to appropriately address the unsettled issues in the management of patients with asymptomatic and symptomatic carotid stenosis, such RCTs are not likely to take place in the near future. The CREST-2, for instance, is not likely to report its outcomes before 2022.
12 What should clinicians do until then? Should they continue their current practice based on the results of outdated RCTs or should they change their practice based on the recent calls for revisiting the management of carotid patients? [4] [5] [6] [7] [8] Although there is evidence suggesting that a change in practice in certain areas is required, the latter may be considered too risky without solid proof and level I evidence. Even though such changes are not likely to happen on a global scale, individual countries have already modified their approach regarding some of these issues at a national level. In Denmark, for example, CEA is only offered to symptomatic patients, while all asymptomatic patients are managed with BMT. 30 Such a national change is an example of the first steps to more extensive changes.
Another option that should be implemented as soon as possible is the creation of comprehensive national and international registries. 14, 15, [30] [31] [32] Although inferior to RCTs in some aspects, such registries provide a roadmap and a guiding tool for clinicians. Finally, several methods have been proposed to identify asymptomatic patients at higher than average risk for stroke. 33 The use of these methods to accurately identify individuals at high stroke risk should be investigated in appropriately designed trials and within registry databases.
We also need to consider that if patients with asymptomatic carotid stenosis are comprehensively investigated, established vascular disease (eg, coronary arterial disease, peripheral arterial disease, and/or abdominal aortic aneurysm) or diabetes may be found. These conditions represent coronary arterial disease equivalents necessitating aggressive vascular risk factor management. Whether patients with asymptomatic carotid stenosis with substantial vascular disease in other arterial beds are at a greater risk of carotid-related events than those without disease elsewhere is not established. Such information would emerge from comprehensive registries as well as RCTs. In turn, this information may help decision-making regarding the need for carotid interventions in asymptomatic patients. Registries may also provide the opportunity to evaluate the predictive ability of risk equations that include several factors (eg, history, biochemical markers, imaging characteristics, and the presence/ absence of carotid bruits). [34] [35] [36] [37] [38] In this context, there is evidence that carotid bruits predict the risk of stroke in patients with diabetes as well as predicting the presence of vascular risk factors and vascular events in other arterial beds. [34] [35] [36] There is even evidence that CEA may improve arterial stiffness, a predictor of vascular risk. 38 Statins improve carotid plaque echogenicity/morphology and carotid intima-media thickness (cIMT). [39] [40] [41] [42] If cIMT and carotid plaque imaging do not improve with BMT, this may be another indicator that a prophylactic carotid intervention is warranted. This could be recorded and evaluated in registries and RCTs. Finally, although nobody disputes the value of BMT as an essential component in the management of patients with asymptomatic and symptomatic carotid stenosis, 13, 43 future research should aim at identifying those asymptomatic patients at higher stroke risk and offer them prophylactic CEA (or even CAS, in certain cases).
Conclusions
It is becoming increasingly apparent that certain controversial issues in the management of patients with carotid artery stenosis need to be urgently addressed. The uncertainty and the lack of a definitive management plan/pathway only hampers the quality of service provided. The optimal management of asymptomatic patients is a crucial issue. The demise of SPACE-2, 11 one of the very few contemporary RCTs which included a BMT arm alongside CEA and CAS in asymptomatic patients was a serious blow to resolving the never-ending conflict between CAS, CEA, and BMT. 44 Currently, only a couple of studies are attempting to resolve the controversy in the management of asymptomatic carotid artery stenosis, such as CREST-2. 12 The CREST-2, however, only started randomizing patients in 2015 and it will be several years before its results are published. It is imperative that the issue of appropriate patient selection for carotid revascularization procedures is urgently addressed and resolved. [45] [46] [47] [48] 
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